[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"treatment-of-spontaneous-intracerebral-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:treatment-of-spontaneous-intracerebral-hemorrhage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100415226","safety-and-efficacy-of-stereotactic-aspiration-plus-urokinase-in-deep-intracerebral-hemorrhage-evacuation-100415226",false,"NCT04686877","Safety and Efficacy of Stereotactic Aspiration Plus Urokinase in Deep Intracerebral Hemorrhage Evacuation","Safety and Efficacy of Stereotactic Aspiration Plus Urokinase in Deep Intracerebral Hemorrhage Evacuation: a Multicentral Randomized, Controlled, Open-label, Trial","STAPLE-dICH","Inclusion criteria:\n\n1. aged 40 years or older;\n2. the duration from onset to the baseline computed tomography angiography (CTA) scan was between 6 to 24 hours;\n3. patients with a spontaneous ICH in the deep brain parenchyma (≥1 cm from the cortical surface); with hematoma volume more than 25 ml (measured with the ABC\u002F2 method); without hydrocephalus caused by intraventricular hemorrhage; without cerebral herniation and the benefit of surgical treatment was unknown;\n4. The Glasgow Coma Scale (GCS) ranged from 9 to 15;\n5. patients with motor deficits;\n6. The modified Rankin Score (mRS) ranged from 0 to1 before onset.\n\nExclusion Criteria:\n\n1. ICH was caused by aneurysms, arteriovenous malformations, tumors, or trauma;\n2. patients had a history of intracerebral hemorrhage or ischemic cerebral infarction;\n3. patients had severe coagulation disorders with INR ≥ 1.5;\n4. patients had severe underlying diseases, which may affect the outcomes;\n5. pregnant and lactating patients;\n6. patients refused to sign the informed consent and receive follow-up.","ALL","40 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a nationwide, multicenter, open-label, randomized controlled trial of early minimally invasive treatment for deep-seated spontaneous cerebral hemorrhage (dICH). The study consists of 2 steps: the first step is to conduct a dose climbing test to determine the safety and optimal dose of urokinase intra-hematoma irrigation after stereotactic aspiration; the second step is to validate whether stereotactic aspiration plus urokinase irrigation (the optimal dose determined in step one) is superior to conservative treatment in improving long-term outcomes (1 year) in early (within 24h) dICH patients.",[27],"Treatment of Spontaneous Intracerebral Hemorrhage",[29,30,31,32,33],"Deep-Seated Spontaneous Intracerebral Hemorrhage","Stereotactic Aspiration","Urokinase Irrigation","Randomized Controlled Trial","Long-term outcome","RECRUITING","2025-02-08",{"date":37,"type":38},"2025-02-12","ACTUAL",{"date":40,"type":38},"2021-01-31",{"date":42,"type":21},"2025-09-30",{"name":44,"class":45},"First Affiliated Hospital of Fujian Medical University","OTHER"]